Evaluation of spin in oncology clinical trials.

Abstracts Bias Overall survival Randomized controlled trial Spin Surrogate endpoints

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 19 02 2019
revised: 08 10 2019
accepted: 14 10 2019
pubmed: 17 11 2019
medline: 8 2 2020
entrez: 17 11 2019
Statut: ppublish

Résumé

Spin, the misrepresentation of research findings, in clinical trial abstract has been shown to influence how oncologist rate a drug's efficacy. We searched PubMed for clinical trials published in ten key journals in 2017. Our primary objectives were to assess the frequency and manifestations of spin in the abstracts of those clinical trials that measured both overall survival and at least one surrogate efficacy endpoints. 124 trials were included for analysis. We found evidence of spin in 46 of 124 (37.1%, 95% CI 29.1%-45.9%) trial abstracts. Spin in the abstract results was most often due to authors emphasizing a statistically significant subgroup analysis (n = 6). Spin in the abstract conclusions was most often due to authors relying on a statistically significant surrogate endpoint to highlight the bioefficacy of the intervention (n = 17). Spin is prevalent in the abstracts of oncology clinical trials that measure OS and a surrogate endpoint. The conclusion sections of abstracts were most prone to contain spin. When OS was the primary endpoint, spin was primarily used to distract from the nonsignificant OS data. To mitigate unintentional hype for cancer therapies, we recommend authors structure their conclusions around patient-important outcomes.

Identifiants

pubmed: 31733444
pii: S1040-8428(19)30193-3
doi: 10.1016/j.critrevonc.2019.102821
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102821

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

C Wayant (C)

Oklahoma State University Center for Health Sciences, Department of Biomedical Sciences, 1111 West 17th Street, Tulsa, OK, 74107, USA. Electronic address: cole.wayant@okstate.edu.

D Margalski (D)

Wake Forest Baptist Medical Center, Department of Internal Medicine, 1 Medical Center Blvd, Winston-Salem, NC, 27157, USA. Electronic address: daniel.margalski@okstate.edu.

K Vaughn (K)

University of Oklahoma School of Community Medicine, Department of Medicine/Pediatrics, 4502 E. 41st Street, Tulsa, OK, 74135, USA. Electronic address: kaleb.vaughn@okstate.edu.

M Vassar (M)

Oklahoma State University Center for Health Sciences, Department of Psychiatry, 1111 West 17th Street, Tulsa, OK, 74107, USA. Electronic address: matt.vassar@okstate.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH